CTOs on the Move


 
FYI is a productivity tool for creatives that allows users to organize their work into projects, store files, manage assets, add team members and guests, and share and sync content. It is a secure platform that helps teams to focus their ideas.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.fyi.me
  • 10960, Wilshire Boulevard
    Los Angeles, CA USA 90024

Executives

Name Title Contact Details

Similar Companies

Clearway Technology Partners

Star Information Technology is a private company categorized under Prepackaged Software and located in Medfield, MA. Current estimates show this company has an annual revenue of less than $500,000 and employs a staff of approximately 1 to 4

Dealer-FX

Since 2007, Dealer-FX has been transforming how automotive retailers manage their service operations and how they interact with consumers. Through advanced data integrations and mobile technology, Dealer-FX streamlines processes and communication for automotive service departments while delivering convenience, transparency and trust to consumers. From service scheduling to vehicle write-up, through to delivery, the Dealer-FX ONE Platform helps dealerships increase efficiency, profitability, retention and brand loyalty. Dealer-FX is the exclusive, or preferred service technology provider for many leading OEMs including FCA, Nissan, Infiniti, Toyota, Lexus, Mitsubishi, GM, Kia and Hyundai and works with thousands of automotive retailers in the US, Canada, and Puerto Rico. Dealer-FX is based in Toronto, ON.

Woebot

Meet Woebot, your personal mental health ally that helps you get back to feeling like yourself. Backed by clinical research, powered by AI.

Armeta Analytics

Data is the fuel that powers your business. Speed, cost, and innovation are just a few of the benefits you will achieve with the right analytics strategy.

Immunome

Immunome is a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system. Our unique and powerful immunotherapy discovery engine leverages “most highly educated” immune systems from patients who have already learned how to fight off their disease. This proprietary technology platform enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens. We then employ a battery of high-content screening technologies to identify specific and high-affinity antibodies that offer significant therapeutic potential to change the way we treat cancer.